IDEAYA Biosciences, Inc. (IDYA) Stock Price & How to Invest

IDEAYA Biosciences, Inc. (Nasdaq: IDYA) is a clinical-stage precision-medicine oncology company that designs targeted therapies for molecularly defined solid tumors. Its scientific engine is synthetic lethality, an approach that exploits genetic vulnerabilities specific to cancer cells, supported by an in-house DECIPHER CRISPR platform for target and biomarker discovery. The lead asset, darovasertib (IDE196), is a protein kinase C inhibitor being developed for uveal melanoma, a rare and hard-to-treat eye cancer, in both the metastatic setting (with crizotinib, partnered with Servier) and as neoadjuvant and adjuvant therapy for primary disease. Behind it sits a pipeline including IDE397 (MAT2A inhibitor) for MTAP-deleted cancers, IDE849 (a DLL3-targeting topoisomerase-I ADC), IDE161 (PARG), IDE275 (Werner helicase), and IDE705 (Pol-theta helicase).

The investment picture is a classic development-stage biotech story: little to no product revenue today, ongoing operating losses funded by a large cash balance, and value that is driven almost entirely by clinical data and regulatory milestones. In Q1 2026 the pivotal Phase 2/3 OptimUM-02 trial of darovasertib plus crizotinib met its primary endpoint (hazard ratio 0.42, median progression-free survival 6.9 vs 3.1 months), setting up an NDA submission planned for H2 2026 under the FDA's Real-Time Oncology Review program. The company reported roughly $973 million in cash and marketable securities as of March 31, 2026, with runway guided into 2030, giving it capacity to fund multiple programs. The debate is whether darovasertib gains approval and commercial traction and whether the earlier pipeline delivers, against the dilution and binary-outcome risks inherent to biotech.

As a clinical-stage biotech, IDEAYA has minimal product revenue and posts ongoing operating losses, so the equity is valued on pipeline expectations that can swing sharply on trial and regulatory news. The FDA could delay or decline the darovasertib NDA, or approval could come with a narrow label or slow commercial uptake in a rare indication. Earlier-stage programs (IDE397, IDE849, IDE161 and others) carry high failure rates typical of oncology drug development. Despite a large cash balance, continued spending and a recent shelf registration point to future dilution as a likely funding mechanism. The company also faces competition from established and emerging therapies in its target indications, and the stock is historically volatile around data catalysts.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see IDEAYA Biosciences, Inc.'s investor relations page or your broker.

• Product revenue: ~$0 (pre-commercial; Q1 2026 collaboration revenue ~$6.6M)
• Cash & marketable securities: ~$973M (Mar 31, 2026)
• Cash runway: guided into 2030
• Market cap: ~$2.5-3.2B
• Lead-asset status: darovasertib NDA planned H2 2026 (FDA RTOR)
• Analyst 12-month target (avg): ~$52 (range ~$36-81)

IDEAYA is pre-product-revenue, so traditional multiples like P/E do not apply and the market values it on pipeline probability and cash runway rather than earnings. The roughly $973 million cash balance against a market cap in the low-single-digit billions means a large share of the valuation sits in the balance sheet plus darovasertib option value. Consensus analyst sentiment has been broadly positive, though price targets were trimmed during 2026 (for example RBC to $48), reflecting how tightly the shares track clinical and regulatory expectations.

There are three common ways to get IDYA exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so IDYA sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where IDYA fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

IDEAYA is a cash-rich, catalyst-driven cancer biotech whose value hinges on darovasertib's H2 2026 NDA and a broad synthetic-lethality and ADC pipeline, with binary clinical and regulatory risk in exchange for that optionality.

Whether IDYA is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is IDYA a buy?, and where the stock could go from here in the IDYA stock forecast.

For income investors, whether IDYA pays a dividend and how the payout looks is covered in does IDYA pay a dividend?